These biotech names are ripe for mergers: Analysts By: CNBC.com News May 10, 2015 at 11:00 AM EDT Synageva isn't the only eligible takeout target in biotech. Meg explains who industry analysts are pointing to as the next takeout candidates. Read More >> Related Stocks: Alexion Pharmaceuticals Biomarin Pharmaceuticals Deutsche Bank Ag Gilead Sciences Sanofi-Aventis S.A. ADR Shire Plc Ads Vertex Pharmaceuticals